MedTrace Logo

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2026-04-02

No results posted yet for this study

Summary

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Conditions

  • ALK Positive Malignancies

Interventions

DRUG

ceritinib

hard gelatin capsule or hard tablet for oral use up to 750 mg

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-11
Primary Completion
2027-06-09
Completion
2027-06-09

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Bulgaria
  • China
  • Colombia
  • Czechia
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Lebanon
  • Malaysia
  • Poland
  • Russia
  • Singapore
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584933 on ClinicalTrials.gov